Data-centric machine learning prioritizes compounds for Trypanosoma cruzi assays
Ensemble supervised classifiers trained on curated phenotypic activity data prioritized eight repurposing compounds for clinically relevant parasite-stage assays. The article reports six selected compounds with predicted trypanocidal effects, while identifying cytotoxicity as a caveat for two amastigote candidates; mifepristone showed trypomastigote activity. These are in-vitro strain-specific outcomes, not clinical efficacy or novel molecular entities.
Technology: Ensemble molecular-descriptor linear classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports eight in-silico hits and selected-stage experimental confirmation; tables qualify cytotoxicity caveats.
- Still unknown: Prior compound activity and some full model/supplement details remain for later audit; selected repurposed compounds are not novel molecules.
- AI role: Data-centric supervised ensembles prioritize repurposing candidates for distinct parasite-stage assays.
Evidence sources: https://doi.org/10.3390/pharmaceutics17121513
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text and tables. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.